Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype

JAMA

Volumn 312, Issue 1, 2014, Pages 48-56

  Hsieh, Matthew M ^a,b   Fitzhugh, Courtney D ^a,b   Weitzel, R Patrick ^a,b   Link, Mary E ^a,b   Coles, Wynona A ^a,b   Zhao, Xiongce ^a   Rodgers, Griffin P ^a,b   Powell, Jonathan D ^c   Tisdale, John F ^a,b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; HEMOGLOBIN; HLA ANTIGEN; IRON; MORPHINE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL DISEASE; ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG USE; ECHOCARDIOGRAPHY; ENGRAFTMENT; FEMALE; HISTOCOMPATIBILITY; HLA MATCHING; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; LUNG FUNCTION TEST; LUNG PRESSURE; MALE; NEUROIMAGING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PAIN; PATIENT SAFETY; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBOTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; STEM CELL MOBILIZATION; T LYMPHOCYTE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANEMIA, SICKLE CELL; ANTIBODIES, MONOCLONAL, HUMANIZED; BETA-THALASSEMIA; CHIMERISM; ERYTHROCYTES; FEMALE; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; MALE; MIDDLE AGED; PAIN; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SIROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 84903625438     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.7192     Document Type: Article

References (36)

1. Pauling L, Itano HA. Sickle cell anemia a molecular disease. Science. 1949;110(2865):543-548.
2. Walters MC, Patience M, Leisenring W, et al Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996;335(6):369-376. (Pubitemid 26257244)
3. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998;22(1):1-6. (Pubitemid 28330528)
4. Bernaudin F, Socie G, Kuentz M, et al; SFGM-TC. Long-term results of relatedmyeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749-2756. (Pubitemid 47523201)
5. Andreani M, Nesci S, Lucarelli G, et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 2000;25 (4):401-404. (Pubitemid 30114034)
6. Walters MC, Patience M, Leisenring W, et al; Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7(12):665-673. (Pubitemid 34055819)
7. Andreani M, Testi M, Gaziev J, et al. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica. 2011;96(1):128-133.
8. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 2003;9(8):519-528. (Pubitemid 38351796)
9. Krishnamurti L, Kharbanda S, Biernacki MA, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008;14(11):1270-1278.
10. van Besien K, Bartholomew A, Stock W, et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2000;26(4):445-449. (Pubitemid 30649562)
11. Zheng Y, Collins SL, Lutz MA, et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol. 2007;178(4): 2163-2170. (Pubitemid 46233414)
12. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361(24): 2309-2317.
13. Powars DR, Elliott-Mills DD, Chan L, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med. 1991;115(8):614-620.
14. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895. (Pubitemid 38252536)
15. Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood. 2011;118(5): 1197-1207.
16. Kang EM, Areman EM, David-Ocampo V, et al. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood. 2002;99(3):850-855. (Pubitemid 34525545)
17. Nakamura R, Cortez K, Solomon S, et al. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease inmyeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;30 (4):235-242. (Pubitemid 35023596)
18. Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and MarrowTransplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-1238.
19. Fitzhugh CD, Hsieh MM, Bolan CD, Saenz C, Tisdale JF. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy. 2009;11(4):464-471.
20. Nollet F, Billiet J, Selleslag D, Criel A. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transplant. 2001;28(5):511-518. (Pubitemid 33069631)
21. Srinivasan R, Takahashi Y, McCoy JP, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol. 2006;133(3):305-314.
22. Chalandon Y, Passweg JR, Schmid C, et al; Chronic Leukemia Working Party of European Group for Blood and Marrow Transplantation. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2010;45(3):558-564.
23. Marsh RA, Vaughn G, Kim MO, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116 (26):5824-5831.
24. Bar M, Sandmaier BM, Inamoto Y, et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant. 2013;19(6):949-957.
25. Anurathapan U, Pakakasama S, Rujkijyanont P, et al. Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control. Biol Blood Marrow Transplant. 2013;19(8):1259-1262.
26. Fitzhugh CD, Weitzel RP, Hsieh MM, et al. Sirolimus and post-transplant Cy synergistically maintainmixed chimerism in amismatched murine model. Bone Marrow Transplant. 2013;48(10):1335-1341.
27. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94 (9):3234-3241. (Pubitemid 29512733)
28. Anasetti C, Logan BR, Lee SJ, et al; Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16): 1487-1496.
29. Waickman AT, Powell JD. Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells. J Immunol. 2012;188(10):4721-4729.
30. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet. 2001;357(9257):680-683. (Pubitemid 32206427)
31. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651. (Pubitemid 37430269)
32. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004;103 (11):4023-4027. (Pubitemid 38685339)
33. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore). 2005;84(6):363-376. (Pubitemid 41668935)
34. Fitzhugh CD, Unno H, Hathaway V, et al. Infusion of hemolyzed red blood cells within peripheral blood stem cell grafts in patients with and without sickle cell disease. Blood. 2012;119(24): 5671-5673.
35. Anker SD, Comin Colet J, Filippatos G, et al; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-2448.
36. Bolaños-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285-4291.